Eli Lilly Share Price – Current Levels and Analysis
Eli Lilly (NYSE: LLY) commands attention as one of the pharmaceutical sector’s most closely watched equities. The Indianapolis-based drugmaker’s shares have experienced significant volatility in recent sessions, with trading levels fluctuating between approximately $935 and $956 amid broader market repositioning.
The stock’s recent performance reflects complex dynamics surrounding its GLP-1 drug portfolio, including Mounjaro and Zepbound, alongside shifting analyst sentiment. With a market capitalization hovering between $776 billion and $884 billion, Eli Lilly maintains its position as a healthcare heavyweight despite recent downward pressure.
Current trading data reveals a company navigating between recent 18-week lows and the lingering proximity to its all-time high of $972.53 reached in August 2024. Investors now scrutinize upcoming earnings and pipeline developments for directional cues.
What Is the Current Eli Lilly Share Price?
- Trading near 18-week lows with shares hitting $956.91, levels not seen since November 2025
- Volatility metrics indicate 1.89% price swings with a defensive beta of 0.64 relative to broader markets
- Fiscal Q4 2025 earnings significantly exceeded consensus, reporting $7.54 versus $7.16 expected
- Analyst price targets span a wide $490 range, from bearish $700 to bullish $1,190
- Recent downgrades from Daiwa Securities and Leerink Partners signal near-term caution among institutional watchers
- The stock trades approximately 15% below its August 2024 all-time high of $972.53
- GLP-1 medications Mounjaro and Zepbound continue anchoring long-term growth narratives amid short-term volatility
| Metric | Value | Context |
|---|---|---|
| Current Price Range | $935.58 – $956.91 | Near 18-week low |
| Market Capitalization | $776.19B – $884.13B | Among largest global pharma |
| P/E Ratio (TTM) | 40.76 – 54.80 | Premium valuation multiple |
| Dividend Yield | 0.67% – 0.73% | Indicated annual |
| EPS (TTM) | $15.11 (Basic) | Net income $10.59B |
| Beta | 0.64 | Lower volatility than market |
| 52-Week Range | $623.78 – $1,133.95 | Wide trading band |
| Next Earnings | April 30, 2026 | FY2026Q1 consensus $3.34 |
| Average Volume | 3.28M shares | Recent: 2.73M |
Live chart data indicates the stock has established support channels between $709 and $780, with resistance forming near previous highs. TradingView displays these technical patterns alongside real-time price action, while Eli Lilly’s investor relations portal provides 15-minute delayed quotes via LSEG data feeds.
Eli Lilly Stock Price Target and Forecast
Wall Street analysts maintain divergent outlooks on LLY’s trajectory, reflecting uncertainty about growth sustainability and market competition. Current projections stretch from conservative bearish targets to aggressive bullish scenarios that would require significant multiple expansion.
Analyst Consensus and Price Targets
The consensus price target range spans $700 to $1,190, representing potential downside of 25% or upside of 25% from current trading levels. This dispersion reflects fundamental disagreements about the durability of GLP-1 drug revenues and the appropriate valuation multiple for the sector.
Recent institutional actions have tilted negative. On August 18, 2025, Daiwa Securities downgraded the stock to Neutral with a $700 target, citing valuation concerns. Leerink Partners followed on August 7, 2025, reducing their rating to Market Perform with a $715 price objective. These adjustments contributed to the recent pressure on shares.
Both Daiwa Securities and Leerink Partners issued downgrades in August 2025, adjusting targets to $700 and $715 respectively. These actions shifted sentiment from previous overweight positions, contributing to the stock’s decline toward 18-week lows.
Investment Outlook and Risk Factors
Quantitative models from Trading Economics project a Q1 2026 price level of $851.89, with 12-month forecasts centering around $777.50. Technical traders note bearish correction scenarios targeting $17–$35 in extreme downside cases, while bull flags suggest $1,250 could materialize if resistance at $972–$973 breaks decisively.
The wide forecast dispersion stems from unanswered questions about Medicare pricing negotiations, commercial insurance coverage for obesity indications, and competitive dynamics with Novo Nordisk’s established Ozempic and Wegovy franchises.
Why Is Eli Lilly Stock Price Volatile?
Recent price weakness stems from a confluence of technical breakdowns, analyst downgrades, and sector rotation rather than fundamental business deterioration. The stock has breached 4-week and 18-week support levels, triggering algorithmic selling pressure that extended declines toward the $930–$957 trading range.
Product Pipeline Impact
Tirzepatide-based therapies Mounjaro and Zepbound remain the primary revenue engines, driving earnings beats that exceeded consensus by 5–10% in recent quarters. The Q4 2025 results posted on February 4, 2026, showed actual EPS of $7.54 against $7.16 estimates, demonstrating continued pharmaceutical execution despite stock price weakness.
Mounjaro and Zepbound, the company’s GLP-1 receptor agonists for diabetes and weight management, continue generating revenue growth that supports the elevated P/E multiple despite recent share price declines.
Competitive Position
Eli Lilly competes directly with Novo Nordisk in the expanding obesity therapeutics market. While Lilly commands a higher market capitalization (approximately $800 billion versus Novo Nordisk’s typical range), both face similar reimbursement headwinds and manufacturing constraints. Lilly’s higher P/E ratio reflects investor expectations for superior growth, a premium that becomes vulnerable during risk-off market environments.
Eli Lilly Dividends, Financials, and How to Buy
Income-oriented investors note the indicated dividend yield of 0.67% to 0.73%, providing modest cash returns despite the growth-stock classification. The company maintains solid earnings coverage with basic EPS of $15.11 and net income of $10.59 billion over the trailing twelve months.
Dividend and Financial Metrics
The payout ratio remains conservative, preserving capital for research and development of the Alzheimer’s and oncology pipelines. Financial data from Robinhood and TradingView confirms the dividend yield has remained stable despite share price volatility throughout 2025 and early 2026.
The 52-week range of $623.78 to $1,133.95 indicates significant historical volatility. Investors should verify current pricing across multiple sources before executing trades, as real-time fluctuations can create execution discrepancies. For those interested in learning more about the factors contributing to elevated cholesterol levels, you can find detailed information at $What causes high cholesterol.
Purchasing Shares
LLY trades on the New York Stock Exchange under ticker symbol LLY. Retail investors access shares through standard brokerage accounts, retirement plans, and direct investment platforms. Nasdaq provides market activity data despite the NYSE primary listing. Shares can be purchased pre-market and after-hours through participating brokers, though liquidity may vary during extended sessions.
Eli Lilly Stock History: Key Milestones
-
September 21, 1977: Historical low of $2.04 established during early public trading years.
— TradingView Historical Data -
August 22, 2024: All-time high of $972.53 reached during peak GLP-1 enthusiasm.
— TradingView Historical Data -
October 30, 2025: Q3 FY2025 earnings beat with $7.02 actual versus $6.36 consensus.
— Trading Economics -
February 4, 2026: Q4 FY2025 earnings report delivers $7.54 actual versus $7.16 expected.
— Trading Economics -
August 7, 2025: Leerink Partners downgrades to Market Perform with $715 target.
— FinViz -
August 18, 2025: Daiwa Securities issues downgrade to Neutral, cutting target to $700.
— FinViz -
April 30, 2026: Scheduled Q1 FY2026 earnings (consensus estimate $3.34).
— Trading Economics
Established Facts vs. Outstanding Uncertainties
Verified Information
- Current trading range between $935.58 and $956.91
- Market capitalization of $776.19B to $884.13B
- Recent earnings beats in Q3 and Q4 FY2025
- Dividend yield indicated at 0.67%–0.73%
- Next earnings date scheduled for April 30, 2026
- 52-week trading boundaries at $623.78 and $1,133.95
Remaining Uncertainties
- Trajectory toward extreme bullish targets of $1,250
- Impact of Q1 2026 guidance on valuation multiples
- Regulatory timelines for pipeline drug approvals
- Sustainability of P/E ratios above 40x in rising rate environments
- Commercial pricing outcomes for Medicare negotiations
The Pharmaceutical Sector Context
The intersection of pharmaceutical innovation and personal health monitoring continues evolving, with devices like the Samsung Galaxy Watch Active – Specs, Battery and 2024 Review demonstrating how patients track metabolic health alongside medication regimens. This convergence underscores the expanding addressable market for Lilly’s diabetes and obesity therapeutics.
Visual documentation remains crucial in medical education; resources such as Herpes Photos in Different Stages – Visual Stages from Prodrome to Healing illustrate diagnostic protocols that complement pharmaceutical research methodologies. Similarly, Eli Lilly’s emphasis on evidence-based outcomes requires rigorous clinical documentation to support regulatory filings and prescriber confidence.
Competition with Novo Nordisk intensifies as both companies expand manufacturing capacity for GLP-1 drugs. While Lilly’s market cap exceeds its Danish rival, both face similar pressures regarding insurance coverage, supply chain constraints, and the eventual entry of oral formulations that could disrupt the injectable-heavy current market.
What Analysts and Official Sources Say About LLY
Technical analysis suggests bearish correction scenarios targeting $17–$35 represent extreme downside outliers, while bullish flag formations indicate $1,250 could materialize if resistance at $972–$973 breaks with institutional volume confirmation.
— TradingView Technical Analysis Community, September 2025
The downgrade to Neutral reflects valuation concerns following the stock’s previous run-up, with our $700 target price based on normalized P/E multiples for the large-cap pharmaceutical sector.
— Daiwa Securities Research Note, August 18, 2025
Market Perform rating acknowledges the company’s strong fundamental execution in the GLP-1 space while recognizing near-term headwinds from competitive pricing pressure and reimbursement negotiations.
— Leerink Partners Equity Research, August 7, 2025
Key Takeaways on Eli Lilly’s Share Price
Eli Lilly trades near 18-week lows around $935–$956, reflecting analyst downgrades and technical selling pressure despite solid earnings execution. The wide analyst target range ($700–$1,190) reflects fundamental uncertainty about GLP-1 drug sustainability and appropriate valuation multiples. Investors weighing entry points must balance the company’s pharmaceutical innovation against near-term volatility and regulatory risks. Samsung Galaxy Watch Active – Specs, Battery and 2024 Review offers perspective on companion health technologies within the sector.
Frequently Asked Questions
What is Eli Lilly known for?
Eli Lilly specializes in pharmaceutical development, particularly diabetes treatments including the GLP-1 drugs Mounjaro and Zepbound, oncology therapeutics, and neuroscience medications including Alzheimer’s research compounds.
Does Eli Lilly pay dividends?
Yes, Eli Lilly pays quarterly dividends with an indicated annual yield ranging from 0.67% to 0.73%, representing a modest income component alongside growth-oriented capital appreciation.
What is the 52-week range for LLY stock?
LLY has traded between $623.78 (low) and $1,133.95 (high) over the past 52 weeks, demonstrating significant volatility and a wide trading band for strategic entry considerations.
When did Eli Lilly stock reach its all-time high?
The stock reached its all-time high of $972.53 on August 22, 2024, during peak investor enthusiasm for the company’s tirzepatide-based obesity and diabetes treatments.
How does Eli Lilly compare to Novo Nordisk?
Both compete in the GLP-1 market, with Lilly offering Mounjaro/Zepbound versus Novo’s Ozempic/Wegovy. Lilly commands a higher market cap and P/E multiple, reflecting growth expectations.
What is the next earnings date for Eli Lilly?
The company reports Q1 FY2026 earnings on April 30, 2026, with consensus analyst estimates projecting earnings per share of $3.34.
Is Eli Lilly stock currently undervalued?
Valuation assessments vary: the P/E of 40.76–54.80 exceeds sector averages, suggesting growth premium pricing. Recent downgrades argue fair value sits near $700–$715, while bulls see upside to $1,190.
More related posts
Leni Klum: Age, Family, Relationship with Seal, Modeling Career
Shonda Rhimes: Biography, Net Worth, Shows & Key Facts
Villarreal vs Real Madrid: Head-to-Head, Stats & 2026 Result
The Picture of Dorian Gray: Plot, Themes & Controversy
Clarkson’s Farm Season 5: Release Date, Episodes & More
Colour Wow Dream Cocktail – Guide to Variants, Usage and Value
Leeds United vs Manchester United FC: timeline and rivalry
1 British Pound to Indian Rupee: £1 in INR Rate
